JP2013510091A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013510091A5 JP2013510091A5 JP2012537218A JP2012537218A JP2013510091A5 JP 2013510091 A5 JP2013510091 A5 JP 2013510091A5 JP 2012537218 A JP2012537218 A JP 2012537218A JP 2012537218 A JP2012537218 A JP 2012537218A JP 2013510091 A5 JP2013510091 A5 JP 2013510091A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- cells
- particle
- polypeptide
- respiratory syncytial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 54
- 239000002245 particle Substances 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 38
- 229920001184 polypeptide Polymers 0.000 claims description 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 15
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 12
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000013603 viral vector Substances 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000003472 neutralizing effect Effects 0.000 claims description 6
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 claims description 4
- 230000001177 retroviral effect Effects 0.000 claims description 4
- 230000002103 transcriptional effect Effects 0.000 claims description 4
- 241000714230 Avian leukemia virus Species 0.000 claims description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 3
- 241000714474 Rous sarcoma virus Species 0.000 claims description 3
- 241000713311 Simian immunodeficiency virus Species 0.000 claims description 3
- 229960000402 palivizumab Drugs 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 241000238631 Hexapoda Species 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 230000013595 glycosylation Effects 0.000 claims description 2
- 238000006206 glycosylation reaction Methods 0.000 claims description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- 210000003125 jurkat cell Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 230000000644 propagated effect Effects 0.000 claims description 2
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 210000003501 vero cell Anatomy 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 230000005847 immunogenicity Effects 0.000 claims 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 claims 1
- 102000003792 Metallothionein Human genes 0.000 claims 1
- 108090000157 Metallothionein Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 241000700605 Viruses Species 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25776609P | 2009-11-03 | 2009-11-03 | |
| US61/257,766 | 2009-11-03 | ||
| PCT/US2010/055334 WO2011056899A2 (en) | 2009-11-03 | 2010-11-03 | Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013510091A JP2013510091A (ja) | 2013-03-21 |
| JP2013510091A5 true JP2013510091A5 (enExample) | 2013-12-19 |
| JP5917402B2 JP5917402B2 (ja) | 2016-05-11 |
Family
ID=43970730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537218A Expired - Fee Related JP5917402B2 (ja) | 2009-11-03 | 2010-11-03 | キメラＲＳＶ−Ｆポリペプチド、およびレンチウイルスＧａｇまたはアルファレトロウイルスＧａｇに基づくＶＬＰ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8920812B2 (enExample) |
| EP (1) | EP2496609A4 (enExample) |
| JP (1) | JP5917402B2 (enExample) |
| CN (1) | CN102753582A (enExample) |
| WO (1) | WO2011056899A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9296790B2 (en) | 2008-10-03 | 2016-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for protein delivery |
| EP2636413A1 (en) * | 2012-03-09 | 2013-09-11 | Ecole Normale Superieure De Lyon | Chimeric virus-like particles (VLP) containing functional hMPV proteins |
| AP2014007993A0 (en) * | 2012-03-22 | 2014-10-31 | Crucell Holland Bv | Vaccine against RSV |
| US9506041B2 (en) | 2012-03-26 | 2016-11-29 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Delivery of packaged RNA to mammalian cells |
| DK2950886T3 (da) * | 2013-02-01 | 2020-03-23 | Medimmune Llc | Respiratorisk syncytialvirus-f-protein-epitoper |
| WO2015066715A1 (en) * | 2013-11-04 | 2015-05-07 | Viracell Advanced Products, Llc | Virus-like particles and methods related thereto |
| CN113648406A (zh) | 2013-12-16 | 2021-11-16 | 美利坚合众国, 由健康及人类服务部部长代表 | 通过使用vlp复制子投递ii类mhc抗原的癌症免疫疗法 |
| CN104450631A (zh) * | 2014-11-11 | 2015-03-25 | 中国人民解放军第四军医大学 | 肠道病毒ev71型vp1基因病毒样颗粒及其制备方法和应用 |
| AU2017298576B2 (en) | 2016-07-18 | 2023-04-13 | Variation Biotechnologies Inc. | Vaccine compositions for treatment of Zika virus |
| LT3606942T (lt) | 2017-04-04 | 2025-10-10 | Savaiminės sąrankos baltymų nanostruktūros, eksponuojančios paramiksoviruso ir (arba) pneumoviruso f baltymus ir jų naudojimas | |
| JP7277466B2 (ja) | 2017-09-01 | 2023-05-19 | インプラザー エー・ペー・エス | 疾患の予防および／または治療における使用のためのワクチン |
| AU2019228551B2 (en) * | 2018-02-28 | 2025-07-24 | University Of Washington | Self-assembling nanostructure vaccines |
| EP3768239A4 (en) * | 2018-03-21 | 2022-01-19 | The University of North Carolina at Chapel Hill | COMPOSITIONS AND METHODS FOR INHIBITING PATHOGENIC INFECTION |
| WO2020092365A1 (en) | 2018-10-29 | 2020-05-07 | Binh Ha | Rsv virus-like particles and methods of use thereof |
| KR20230008707A (ko) | 2020-03-30 | 2023-01-16 | 배리에이션 바이오테크놀로지스 아이엔씨. | 코로나바이러스 치료용 백신 조성물 |
| EP4351660A2 (en) | 2021-06-09 | 2024-04-17 | Scribe Therapeutics Inc. | Particle delivery systems |
| WO2024254544A2 (en) * | 2023-06-07 | 2024-12-12 | Nvelop Therapeutics, Inc. | Compositions and methods for promoting payload delivery in cells |
| CN117777314B (zh) * | 2024-02-26 | 2024-05-14 | 赛德特生物制药有限公司 | 慢病毒载体及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0941315T3 (da) | 1996-11-26 | 2006-05-15 | Stressgen Biotechnologies Corp | Fusionsproteiner indeholdende stressproteiner til induktion af immunreaktioner |
| US6099847A (en) | 1997-05-15 | 2000-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric Gag pseudovirions |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| WO1999052549A1 (en) | 1998-04-09 | 1999-10-21 | Smithkline Beecham Biologicals S.A. | Adjuvant compositions |
| EP1294892B1 (en) | 2000-06-23 | 2007-10-17 | Wyeth Holdings Corporation | Assembly of wild-type and chimeric influenza virus-like particles (vlps) |
| EP1294858B1 (en) | 2000-06-23 | 2008-12-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES | Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes |
| EP1201750A1 (en) | 2000-10-26 | 2002-05-02 | Genopoietic | Synthetic viruses and uses thereof |
| US6818216B2 (en) | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
| US20030049607A1 (en) | 2001-03-12 | 2003-03-13 | Tsvika Greener | Compositions and methods for the modulation of viral maturation |
| JP4302513B2 (ja) | 2001-07-05 | 2009-07-29 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 抗原性ｂ型ｈｉｖポリペプチドおよび／または抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用 |
| DK1506223T3 (da) | 2002-05-16 | 2006-04-10 | Bavarian Nordic As | Fusionsprotein af regulatoriske/accessoriske HIV-proteiner |
| US9045727B2 (en) | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
| WO2004042001A2 (en) | 2002-05-17 | 2004-05-21 | Emory University | Virus-like particles, methods of preparation, and immonogenic compositions |
| ATE489969T1 (de) | 2002-06-20 | 2010-12-15 | Cytos Biotechnology Ag | Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung |
| GB0226722D0 (en) | 2002-11-15 | 2002-12-24 | Glaxo Group Ltd | Vaccine |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| US8574590B2 (en) | 2003-07-30 | 2013-11-05 | Integral Molecular, Inc. | Lipoparticles comprising proteins, methods of making, and using the same |
| US8437251B2 (en) | 2005-12-22 | 2013-05-07 | Qualcomm Incorporated | Methods and apparatus for communicating transmission backlog information |
| WO2008094197A2 (en) | 2006-07-27 | 2008-08-07 | Ligocyte Pharmaceuticals, Inc. | Chimeric influenza virus-like particles |
| WO2008094200A2 (en) * | 2006-07-27 | 2008-08-07 | Ligocyte Pharmaceuticals, Inc | Chimeric virus-like particles |
| US20080233150A1 (en) * | 2006-11-16 | 2008-09-25 | Gale Smith | Respiratory syncytial virus-virus like particle (vlps) |
| DE102006060799A1 (de) * | 2006-12-21 | 2008-06-26 | RUHR-UNIVERSITäT BOCHUM | RSV F-Protein und seine Verwendung |
| US20100247574A1 (en) * | 2007-02-21 | 2010-09-30 | Kutub Mahmood | CHIMERIC NEWCASTLE DISEASE VIRUS VLPs |
-
2010
- 2010-11-03 WO PCT/US2010/055334 patent/WO2011056899A2/en not_active Ceased
- 2010-11-03 JP JP2012537218A patent/JP5917402B2/ja not_active Expired - Fee Related
- 2010-11-03 EP EP10829045.3A patent/EP2496609A4/en not_active Withdrawn
- 2010-11-03 US US13/505,250 patent/US8920812B2/en not_active Expired - Fee Related
- 2010-11-03 CN CN2010800499077A patent/CN102753582A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013510091A5 (enExample) | ||
| Zhang et al. | A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques | |
| US20230023093A1 (en) | Dna antibody constructs and method of using same | |
| Tornesello et al. | Virus-like particles as preventive and therapeutic cancer vaccines | |
| US20220112273A1 (en) | DNA Antibody Constructs And Method Of Using Same | |
| US10087240B2 (en) | DNA antibody constructs and method of using same | |
| JP2009544318A5 (enExample) | ||
| US12054537B2 (en) | Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies | |
| KR102604877B1 (ko) | 감염성 질환의 예방 및/또는 치료와 종양학적 질환의 치료를 위한 약독화된 인플루엔자 벡터 | |
| JP2010528601A5 (enExample) | ||
| JP2012526839A5 (enExample) | ||
| US11072649B2 (en) | Systems and methods for the production of human polyclonal antibodies | |
| Pandey et al. | Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses | |
| Yu et al. | A recombinant pseudotyped lentivirus expressing the envelope glycoprotein of hantaan virus induced protective immunity in mice | |
| Temchura et al. | Intrastructural help: improving the HIV-1 envelope antibody response induced by virus-like particle vaccines | |
| CA3085627C (en) | Ebola virus and marburg virus glycoprotein mucin-like domain replacement expression system used as new vaccine approaches | |
| Wise et al. | An enhanced synthetic multiclade DNA prime induces improved cross-clade-reactive functional antibodies when combined with an adjuvanted protein boost in nonhuman primates | |
| MX354571B (es) | Genomas lentivirales quimericos no integrativos como vacunas innovadoras contra el virus de la inmunodeficiencia humana tipo 1 (vih-1). | |
| Schell et al. | Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody | |
| Di Vincenzo | Determinants of the Antibody Response against HIV Env induced by Nanoparticle Vaccination and Intrastructural Help | |
| CN117043182A (zh) | 经修饰的抗病毒结合剂 | |
| TW202246317A (zh) | 針對呼吸道融合病毒及其他副黏液病毒的抗體以及使用其之方法 | |
| Hogan | Improving Vaccine Design for Viral Diseases Using Modified Antigens and Vectors | |
| Peng | A novel vaccine strategy: Replication-defective pseudotyped SIVs expressing IFN-γ |